What is hairy cell leukemia and how does it manifest?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hairy Cell Leukemia: Diagnosis and Clinical Manifestations

Hairy cell leukemia (HCL) is a rare B-cell chronic lymphoproliferative disorder characterized by splenomegaly, pancytopenia, and bone marrow involvement with fibrosis, affecting approximately 2% of all adult leukemias. 1

Definition and Epidemiology

  • Represents approximately 2% of all lymphoid leukemias
  • Approximately 1600 new cases diagnosed annually in Europe
  • Median age at diagnosis: 52 years
  • Male predominance with male-to-female ratio of 4:1
  • Higher frequency among white Americans than African-Americans or Asians
  • Possible association with exposure to herbicide "Agent Orange" 1

Pathophysiology

  • B-cell malignancy with cells arrested at a late stage of maturation
  • Characterized by BRAF V600E mutation in most classical HCL cases (not present in HCL variant)
  • Somatic hypermutation in the IGHV gene present in 80-90% of cases
  • Leukemic cells infiltrate bone marrow, spleen, and sometimes liver and lymph nodes 1

Clinical Manifestations

Common Presenting Symptoms

  • Fatigue and weakness (80% of patients)
  • Fever (56% of patients)
  • Abdominal pain
  • Recurrent opportunistic infections 1, 2

Physical Examination Findings

  • Splenomegaly (92% of patients) - most common physical finding
  • Hepatomegaly (28% of patients)
  • Peripheral lymphadenopathy (uncommon) 1, 2

Laboratory Abnormalities

  • Pancytopenia (most common)
  • Anemia
  • Monocytopenia (characteristic)
  • Macrocytosis
  • Occasionally normal blood counts or leukocytosis (rare) 1, 2

Diagnostic Features

Morphological Characteristics

  • Hairy cells: small to medium-sized lymphoid cells with:
    • Round, oval, or indented nucleus
    • Well-defined nuclear border
    • Loose chromatin
    • Abundant pale cytoplasm with characteristic hair-like projections 1

Bone Marrow Findings

  • Frequent "dry tap" (84% of cases) due to increased reticulin fibers
  • Infiltration pattern varies from mild interstitial to diffuse
  • "Fried egg" pattern: lymphoid cells surrounded by clear halo
  • Occasionally hypocellular (can be mistaken for aplastic anemia) 1, 2

Immunophenotypic Profile

  • Typical immunophenotype for classical HCL:
    • CD19+, CD20+ (bright), CD22+
    • CD11c+, CD25+, CD103+, CD123+
    • CD5-, CD10-
    • Cyclin D1+, annexin A1+, CD200+ (bright) 1

Special Diagnostic Tests

  • Tartrate-resistant acid phosphatase (TRAP) staining: highly specific for classical HCL
  • BRAF V600E mutation testing: present in most classical HCL cases
  • Flow cytometry with comprehensive panel 1, 3

Distinguishing Classical HCL from HCL Variant

Feature Classical HCL HCL Variant
Morphology Typical hairy cells Nucleolated cells
Monocytopenia Present Absent
Lymphocyte count Usually low/normal High
CD25 Positive Negative
CD123 Positive Negative
BRAF V600E Positive Negative
TRAP staining Positive Variable
Response to purine analogues Good Poor
[1,3]

Diagnostic Pitfalls and Caveats

  • Bone marrow aspiration frequently results in "dry tap" - rely on biopsy
  • HCL can occasionally present with normal blood counts or even leukocytosis
  • Rare cases may express CD10 (13%) or CD23 (19%)
  • Absence of splenomegaly does not rule out HCL (occurs in 8% of cases)
  • Unmutated IGHV is associated with poorer outcomes and primary refractoriness to purine analogue therapy 1, 2

Early diagnosis is critical as modern treatments with purine analogues (cladribine or pentostatin) can achieve high response rates and durable remissions, significantly improving prognosis in a disease that was historically considered uniformly fatal 4, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnostic Markers for Hairy Cell Leukemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Hairy cell leukemia: current concepts.

Cancer investigation, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.